TY - JOUR T1 - Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF) JO - Circulation PY - 2022/07/26 AU - Lee MMY AU - Gillis KA AU - Brooksbank KJM AU - Allwood-Spiers S AU - Hall Barrientos P AU - Wetherall K AU - Roditi G AU - AlHummiany B AU - Berry C AU - Campbell RT AU - Chong V et al ED - DO - DOI: 10.1161/circulationaha.122.059851 PB - Ovid Technologies (Wolters Kluwer Health) VL - 146 IS - 4 SP - 364 EP - 367 Y2 - 2025/08/13 ER -